Navigation Links
Perrigo Announces Approval for Over-the-Counter Children's Cetirizine Oral Solution
Date:4/14/2008

ALLEGAN, Mich., April 14 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Children's Cetirizine Hydrochloride Oral Solution (Allergy) and Children's Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1mg/mL.

The product will be marketed under store brand labels and is comparable to McNeil Consumer Healthcare's Children's Zyrtec(R) Oral Solution, 1mg/mL, indicated for indoor and outdoor allergy and hives relief. According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the last 12 months ending December 2007 were approximately $80 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval reflects our strategy to be first to market with the important products that make quality healthcare more affordable for our customers."

The Company expects to begin shipping the product immediately.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of th
'/>"/>

SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2008)...dy finds the majority of acute lymphoblastic leuke...t at the time of diagnosis , , MEMPHIS, Ten...at St. Jude Children,s Research Hospital have iden...ells of children with acute lymphoblastic leukemia...thway to designing treatments for ALL relapse in c...
(Date:11/26/2008)...ed information density, automation and intelligent... ultrasound to an all new level , , CHICAGO... Healthcare ( www.siemens.com/healthcare ) hig...me Scanner (ABVS)(1), the world,s first multi-use...e 94th Scientific Assembly and Annual Meeting of t...
(Date:11/25/2008)... awareness can improve recovery , , Audio a... available on the Mayo Clinic News Blog. Please se... , ROCHESTER, Minn., Nov. 25 /PRNewswire-USNe... stroke patients don,t think they,re having a stro...ntil their condition worsens. The findings appear ...
(Date:11/25/2008)... reveal most respondents against expanding statin ..., LITTLE FALLS, N.J., Nov. 25 JU...y lower the cardiovascular risk of healthy patient...tatin use in older adults, according to a national... participants took part in the online poll conduct...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Strawberry fields ripe for the picking 1486 1Strawberry fields ripe for the picking 1486 2Making emergency artery repair safer 7749 1Jury Awards 245 25 Million Malpractice Verdict Against Fort Worth Doctor 7745 1Jury Awards 245 25 Million Malpractice Verdict Against Fort Worth Doctor 7745 2Blue Cross Foundation Invests in Community Health 7741 1Blue Cross Foundation Invests in Community Health 7741 2Blue Cross Foundation Invests in Community Health 7741 3Blue Cross Foundation Invests in Community Health 7741 4
...007 /PRNewswire-FirstCall/ --,Phosphagenics Limite... pre-clinical studies of its TPM-02 dermal drug de... leading topical,treatment for severe acne and an ...The proof of concept studies showed a three-fold i...nto the skin when formulated,with TPM-02 compared ...
...ewswire-USNewswire/ -- Childhood,cancers are fortu...ecial case, accounting for 7 percent of all childh...aths. It typically occurs as a,solid tumor in the ...developing in the network of the body,s sympatheti...ns call a heterogeneous disease;,its name includes...
Other Medicine Technology:Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 3
(Date:12/1/2008)...wire-FirstCall/ -- The Ensign Group, Inc.,(Nasdaq... Rehabilitation Center in,Pocatello, Idaho has su... and,Medicaid Services, Special Focus program. ,...h/20071213/LATH168LOGO ) , A clinical team ...llo Care,& Rehabilitation Center, completed t...
(Date:12/1/2008)..., at Memorial Sloan-Kettering Cancer Center, New Y... expression of genes for therapeutic purposes, and... in mice. , Small, noncoding RNA molecules known... expression. In the study, the miRNA miR-181a was ...ne cells known as T cells at different stages of t...
(Date:12/1/2008)...irstCall/ -- ViroPharma Incorporated,(Nasdaq: V... supplemental,Biologics License Application (sBLA...for Cinryze(TM) C1 Inhibitor (human) as a treatmen...). , The sBLA is based on a re-analysis and...e treatment study of Cinryze and interim data from...
(Date:12/1/2008)...ty illnesses common, study shows , , MO...ders are common among young adults in the United S... , To reach this finding, U.S. researchers anal...9 to 25, who took part in the National Epidemiolog...The study found that 45.8 percent of the 2,188 col...
Breaking Medicine News(10 mins):Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2
...der unsanitary and freezing conditions in the coun...e and shell marine products.// The National Instit...bad conducted a study which reveals that many amon...n working in fish processing units are predominant...
...d that more devastating earthquakes are likely to ...50 years. // They will inflict far greater damage ... in Pakistan. Roger Bilham who has been working i... the past two months, said that a huge amount of e...
... Journal of Psychiatry that antidepressant drugs d...rather decrease the suicide risk. The article also...nt drugs should be closely monitored to find their... dosage can cause adverse conditions. The resea...
...nd news media to increase the awareness about chil...// to increase child survival. The Lancet reports ...achievable, Millennium Development Goal – 4 (MDG) ...en below the age of 5 and MDG-5 wants a reduction ...
Other Medicine News:Health News:Unregulated Fish Industry Harms Health Of Women 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre
Economy Apron, Excellent Protection, Value Priced
Surgical Drop-Off Apron
All Day Comfort for the Lower Body
Medicine Products: